Fox Run Management’s Pacific Biosciences PACB Stock Holding History

Fox Run Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-26,744	Closed	-$100K	–	996
2024 Q1	$100K	Buy	26,744 +1,056	+4%	+$6.18K	0.02%	702
2023 Q4	$252K	Buy	25,688 +2,905	+13%	+$23.8K	0.06%	559
2023 Q3	$190K	Buy	+22,783	New	+$260K	0.06%	569
2023 Q1	–	Sell	-17,789	Closed	-$146K	–	859
2022 Q4	$146K	Buy	+17,789	New	+$153K	0.06%	529
2022 Q3	–	Sell	-14,173	Closed	-$63K	–	770
2022 Q2	$63K	Buy	+14,173	New	+$86.1K	0.03%	486
2016 Q3	–	Sell	-15,000	Closed	-$106K	–	626
2016 Q2	$106K	Sell	15,000 -12,900	-46%	-$118K	0.05%	502
2016 Q1	$237K	Buy	+27,900	New	+$274K	0.16%	298

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fox Run Management's PACB Position: Q2 2024 in Review

Fox Run Management sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 26,744 shares — an estimated $100K sold.

Fox Run Management first reported a position in PACB in Q1 2016 and held it in 7 quarters. The position peaked at $252K in Q4 2023. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

Fox Run Management reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
Fox Run Management sold 26,744 Pacific Biosciences shares in Q2 2024, an estimated $100K.
Fox Run Management first reported a position in Pacific Biosciences in Q1 2016 and held it in 7 quarters.
Fox Run Management's Pacific Biosciences position peaked at $252K in Q4 2023.
228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Fox Run Management's 13F filing for Q2 2024, filed 13 Aug 2024.